Piper Sandler raised the firm’s price target on Edwards Lifesciences (EW) to $100 from $98 and keeps an Overweight rating on the shares. The firm points out the company reported strong Q4 results led by strength in the TAVR business. Altogether, it was an all-around strong update from the company, and Piper feels incrementally positive on the set-up going forward. The firm expects shares to trade well coming off the Q4 print.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- AtriCure downgraded to Neutral from Overweight at JPMorgan
- Closing Bell Movers: Robinhood slips 8% after revenue miss
- Edwards Lifesciences reports Q4 adjusted EPS 58c, consensus 62c
- Edwards Lifesciences sees Q1 adjusted EPS 70c-76c, consensus 69c
- Edwards Lifesciences backs FY26 EPS view $2.90-$3.05, consensus $2.91